13G Filing: James E. Flynn and Neos Therapeutics Inc (NEOS)

Page 1 of 18

Neos Therapeutics Inc (NASDAQ:NEOS): James E. Flynn’s Deerfield Management filed an amended 13D.

You can check out Deerfield Management’s latest holdings and filings here.

Please follow Deerfield Management (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Deerfield Management or update its stock holdings.

Follow James E. Flynn's Deerfield Management

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Deerfield Mgmt 0 1,907,052 0 1,907,052 1,907,052 6.72%
Deerfield Management Company 0 2,633,845 0 2,633,845 2,633,845 9.08%
Deerfield Mgmt III 0 726,793 0 726,793 726,793 2.53%
Deerfield Special Situations Fund 0 1,691,146 0 1,691,146 1,691,146 5.96%
Deerfield Partners 0 127,384 0 127,384 127,384 0.45%
Deerfield International Master Fund 0 88,522 0 88,522 88,522 0.32%
Deerfield Private Design Fund III 0 726,793 0 726,793 726,793 2.53%
James E. Flynn 0 2,633,845 0 2,633,845 2,633,845 9.08%

Page 1 of 18 – SEC Filing

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS
FILED PURSUANT

TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS
THERETO FILED

PURSUANT TO RULE 13d-2(b)

(Amendment No. 1) *

Neos Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

64052L106

(CUSIP Number)

August 21, 2017

(Date of Event Which Requires Filing of
this Statement)

Check the appropriate box to designate the
rule pursuant to which this Schedule is filed:

☐  Rule 13d-1(b)

☒  Rule 13d-1(c)

☐  Rule 13d-1(d)

(Page 1 of 15 Pages)

———-

* The remainder of this cover page shall be filled out for a
reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment
containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of
1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act
(however, see the Notes).

Follow Neos Therapeutics Inc. (NASDAQ:NEOS)










Page 1 of 18